Adage Capital Partners Gp, L.L.C. T Scan Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.6 Billion
- Q3 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 4,400,000 shares of TCRX stock, worth $18.1 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
4,400,000
Previous 4,400,000
-0.0%
Holding current value
$18.1 Million
Previous $25.7 Million
14.87%
% of portfolio
0.04%
Previous 0.05%
Shares
5 transactions
Others Institutions Holding TCRX
# of Institutions
89Shares Held
41.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.22MShares$21.5 Million9.31% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$20.6 Million1.08% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$18.4 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$12.3 Million0.47% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$11.5 Million0.15% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $78M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...